Review article: anti-adhesion therapies for inflammatory bowel disease - Wikidata - awgldk - TriplyDB

Review article: anti-adhesion therapies for inflammatory bowel disease

Review article: anti-adhesion therapies for inflammatory bowel disease

http://www.wikidata.org/entity/Q26999705

about

Anti-MAdCAM antibody for induction of remission in ulcerative colitis Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Angiogenesis in Inflammatory Bowel Disease Current stage in inflammatory bowel disease: What is next?Medical Therapy of Active Ulcerative Colitis Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives The Immunogenetics of Autoimmune Cholestasis CRK proteins selectively regulate T cell migration into inflamed tissues.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases Introducing vedolizumab to clinical practice: who, when, and how?Coeliac Disease - New Pathophysiological Findings and Their Implications for Therapy Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series.Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)Vedolizumab: first global approval.Management of inflammatory bowel disease in poor responders to infliximab.Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.Vedolizumab for the treatment of moderately to severely active ulcerative colitis.Positioning Therapy for Ulcerative Colitis.Pathway-based approaches to the treatment of inflammatory bowel disease.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects.Optimizing pharmacologic management of inflammatory bowel disease.Alicaforsen for the treatment of inflammatory bowel disease.Vedolizumab in the treatment of Crohn's disease.Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile.Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future.Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.Methionine restriction on oxidative stress and immune response in dss-induced colitis mice.Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases.Novel treatments for inflammatory bowel disease.Melatonin alters amino acid metabolism and inflammatory responses in colitis mice.Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

P2860

Q24187593-35B4B67A-856C-4886-A60F-462D51037B23 Q26750456-152E304E-31A5-46E9-9BB8-417B0DAEB334 Q26769945-1A1CE0DE-0198-4EE0-AE20-E25AF8CC936B Q26777429-EA0627C3-24FB-4027-8ED4-D776C4247308 Q26777729-F640BBDF-358C-4ECF-9510-2CAF679A1002 Q28085134-6D5E6329-42D8-46D9-AA2E-2A94EB13A295 Q28085346-ECDADC99-E1E3-4850-AED2-E659ADBD167B Q30628412-63EA9F24-2C25-473E-88B2-DFE0AEDF9AB9 Q30902172-64C99A54-38FA-4652-AE5D-951139B481CF Q33865208-6CD874D4-43B8-4947-9240-BFE59729347E Q34353032-E19777D6-99EA-4C4F-839F-33CA462753B4 Q35049579-4515864F-2F6B-4829-860C-C5BA7D6E42EF Q35562290-E200C1B4-50AF-4AD4-B4B8-2494323EC7D3 Q35885793-C7BB4139-A496-4EC9-9AEA-316CD35CA26F Q35933419-45025E1F-BDB3-489A-801A-D251B2A06B8C Q36616115-B17681F3-182A-4022-B1EF-37ED6C4A6529 Q36848945-FC46016F-36F9-4EF9-8FBC-5CF73980CC33 Q38225389-D14E5A96-2C18-4278-8325-6E4BBA97AE5B Q38254573-96A3CA89-1B71-42EF-B71F-9419B9EB3DAB Q38293774-1896A4C7-98E6-4DA0-A517-C6F96598BB05 Q38425873-C1145218-F1D5-41D8-ADC3-0BCAE9193565 Q38542903-DAB39E21-BCA9-4DBC-958A-439792F92C0C Q38593257-7975D405-6BC9-4E56-B638-C83143AC9AAA Q38630959-567C25F6-930D-4644-A229-03485F912990 Q38643163-9C6FF4B4-4E2B-46A5-9F5C-60210BB07D82 Q38687407-47F86369-D4D0-4D30-8CF7-D26CAE5671C7 Q38697244-5C677283-2E75-47B0-AD0D-C77EDF5C6909 Q38711584-9C5B5258-5571-47DA-863D-5A2C173F2387 Q38717600-2D04199E-D59B-4F90-9011-12AE6AEEE8F6 Q38816194-A2CFEC56-2D1E-4B81-AB85-2AABC1126339 Q38973323-41649DD3-2B15-4133-BE17-831A5DFAB33C Q38977579-7D967A28-782D-43FB-AC0A-51B3B85BC85F Q39681190-FAFD2C89-B66F-4BBB-BA48-7E114F74A828 Q41280134-D46120E9-9E9B-46D7-B47A-30E4C306AC68 Q42364630-85E950FA-4180-4A0B-A6F2-03D4237F1266 Q47112883-34D25996-1D63-41BD-B084-F3A46D1AE422 Q47563211-E630EC12-AADC-4D3F-9BEA-9ED0588DB0C0 Q47656287-471C040B-311A-4421-B82D-376E88E0D339 Q48151874-CF4B3776-B73F-408A-91F1-01F381D1048F Q48308809-D552CDA7-8214-410A-BC8B-2A2E9D8436A0

P2860

Review article: anti-adhesion therapies for inflammatory bowel disease

http://www.wikidata.org/entity/Q26999705

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Review article: anti-adhesion therapies for inflammatory bowel disease

@ast

Review article: anti-adhesion therapies for inflammatory bowel disease

@en

Review article: anti-adhesion therapies for inflammatory bowel disease

@nl

type

label

Review article: anti-adhesion therapies for inflammatory bowel disease

@ast

Review article: anti-adhesion therapies for inflammatory bowel disease

@en

Review article: anti-adhesion therapies for inflammatory bowel disease

@nl

prefLabel

Review article: anti-adhesion therapies for inflammatory bowel disease

@ast

Review article: anti-adhesion therapies for inflammatory bowel disease

@en

Review article: anti-adhesion therapies for inflammatory bowel disease

@nl

P1433

Q26999705-7AA04834-AD34-4FA0-B122-0A6246DBEF9A

P1476

Q26999705-A9D9CE2E-3342-4C35-A424-D5F5C1342481

P2093

Q26999705-17F58959-7B68-49AB-A73E-8E42053E1620

Q26999705-B687AF06-8E56-40FA-85F2-1EBFBCF57B16

Q26999705-E2BB4A09-7856-4E93-8DAA-B0AB2EC24054

P2860

Q26999705-0063A4CD-7129-4C2A-A72C-18BA89BF5F5F

Q26999705-01FF67C2-C6F2-4692-8B20-C88166739A2D

Q26999705-030C747F-4BCA-4A15-950A-6813AFBEAF0E

Q26999705-09CC7772-7CCB-45E0-A499-C49F2A6BE569

Q26999705-09D8ACBE-A91F-4AE0-B355-019DB40E8695

Q26999705-0A03622F-A0B5-40E1-AB41-42ACF71D028E

Q26999705-0F18D997-D271-4AE5-9FB1-15B8AA4CFF07

Q26999705-1702FE07-B496-430E-8AD7-EF2C794B0518

Q26999705-1A4152E4-1347-411F-B4C1-8371EE26137E

Q26999705-200D08DC-21ED-405A-A3BD-20BF45E039A6

P304

Q26999705-513AB8DD-4605-4E3A-B42A-D50380077809

P31

Q26999705-B01FF57E-1FD3-4702-90A2-60796A3C69CA

P356

Q26999705-181B826E-6F99-4567-BAEA-49FC1E282CD0

P407

Q26999705-466A130D-6C4E-4A18-96DE-2737CB71CB8C

P433

Q26999705-BB5352B5-6003-43D6-84DB-6D6DAC850EAF

P478

Q26999705-06ACEA95-BA1A-4986-8B48-81C27163CB68

P50

Q26999705-F9B0280F-2A25-4A8A-B522-DDB4EB14234E

P577

Q26999705-6A67B5FB-4A6E-4165-A5C9-092746B39501

P698

Q26999705-F798B753-86C6-4E8B-9A35-97DBA5F1D25F

P921

Q26999705-0BB8D990-0BB5-4D0D-9CE6-F6F3D6D11821

Q26999705-5EC6CC24-BAB9-44F1-971B-32DA29BC40D6

P356

P1433

Alimentary Pharmacology & Therapeutics

P1476

Review article: anti-adhesion therapies for inflammatory bowel disease

@en

P2093

G Van Assche

http://www.w3.org/2001/XMLSchema#string

P Rutgeerts

http://www.w3.org/2001/XMLSchema#string

T Lobatón

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Integrins: bidirectional, allosteric signaling machines

Natalizumab for active Crohn's disease

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1

Certolizumab pegol for the treatment of Crohn's disease

Beta2 integrin/ICAM expression in Crohn's disease

P304

579-594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APT.12639

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Séverine Vermeire

P577

2014-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24479980

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases